BSX Boston Scientific

Boston Scientific develops minimally invasive medical devices for cardiology, rhythm management, urology, endoscopy, and neuromodulation. Sector: Healthcare.

Boston Scientific (BSX) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

From a returns-on-capital standpoint, ROIC is 9.56%, WACC is 7.72%, and the economic spread is 1.84%. On balance, the company clears its capital cost hurdle modestly — value creation is present but not emphatic. Supporting metrics show ROE at 12.58% and ROA at 6.48%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

The current pricing of the company reads trailing P/E of 32.38, forward P/E of 18.16, PEG of 0.97. A meaningful compression from trailing to forward P/E implies analysts are projecting earnings growth that could re-rate the company favorably if delivered. The PEG ratio is low enough to suggest the valuation is supported by earnings growth expectations rather than multiple expansion alone. The aggregate current ratio of 1.62 points to adequate liquidity for the company. In aggregate, the valuation reads as fair to moderately stretched — leaving the investment case dependent on earnings execution rather than multiple expansion.

On profitability at each income statement layer, gross margin sits at 68.89%, operating margin at 19.78%, and free cash flow margin at 17.59%. Gross margins are well above average, signaling strong production-level economics across the company. At this operating margin level, the the company demonstrate competent cost management and reasonable earnings durability. Free cash flow margins are strong, reflecting capital-efficient businesses that largely self-fund their growth. Taken together, margins are adequate but uneven, suggesting earnings quality is not uniformly strong across all levels.

Looking at what the company are actually delivering versus what analysts are pricing in, TTM revenue growth of 15.90% indicating top-line growth that is constructive without being speculative. At the same time, the estimated 12-month price change of 60.22%, where target-based upside appears notably strong in the current setup. Revenue growth captures operating momentum, while price targets reflect external expectations that can move with rates, risk appetite, and sector sentiment. Whether current momentum translates into delivered returns will depend on the durability of both top-line trends and the assumptions embedded in analyst targets. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The composite of ROIC spread, valuation, revenue momentum, and analyst expectations delivers a rare alignment of quality and growth that justifies elevated conviction.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.